RaQualia Pharma (4579) Fundamentals 2026 — P/E 153.4x, Revenue Analysis | SniperIQ
RaQualia Pharma (4579) is a JP-listed Healthcare company in Biotechnology with a market capitalization of ¥11.1B, trading at ¥454.00 on the JPX. This SniperIQ fundamentals page covers RaQualia Pharma's valuation (P/E 153.4x, P/B 1.4x), profitability (net margin 1.4%), revenue (¥4.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is RaQualia Pharma's market cap?
RaQualia Pharma (4579) has a market capitalization of approximately ¥11.1B, trading at ¥454.00 on the JPX. Market cap moves with the live share price.
What is RaQualia Pharma's P/E ratio?
RaQualia Pharma's trailing twelve-month P/E ratio is 153.4x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is RaQualia Pharma?
RaQualia Pharma runs a net profit margin of 1.4%, a gross margin of 77.0%, and an operating margin of 6.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does RaQualia Pharma generate?
RaQualia Pharma reported revenue of ¥4.0B for fiscal year 2025, with net income of ¥273M and earnings per share (EPS) of 11.53. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does RaQualia Pharma pay a dividend?
RaQualia Pharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is RaQualia Pharma financially healthy?
RaQualia Pharma carries a debt-to-equity ratio of 0.34x and a current ratio of 6.16x, with a market beta of 0.90. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is RaQualia Pharma a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For RaQualia Pharma (4579) the key facts are: market cap ¥11.1B, P/E 153.4x, revenue ¥4.0B, 52-week range 440-1465. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track RaQualia Pharma's full fundamentals live
Get RaQualia Pharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.